In ₹ Crore except Per Share Latest Annual | SGRL FY26 | BPLPHARMA FY23 | JENBURPH FY26 | KPL FY24 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 45.45× | ◆ 37.02× | — | — | 37.02× +23% | |
| Growth | ||||||
| Revenue CAGR 3Y | — | — | 7.26% | — | 7.26% | |
| Revenue CAGR 5Y | — | — | 9.07% | — | 9.07% | |
| Net Income CAGR 3Y | — | — | 12.18% | — | 12.18% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 32.04% | 9.80% | 23.81% | 21.69% | 21.69% +48% | |
| Net Income Margin | 16.26% | 11.16% | ◆ 20.59% | — | 15.88% +2% | |
| Return on Common Equity | 10.90% | ◆ 12.74% | — | — | 12.74% -14% | |
| Return on Capital Employed | 13.19% | — | — | ◆ 19.18% | 19.18% -31% | |
| Return on Assets | 8.56% | 7.90% | ◆ 15.37% | — | 11.63% -26% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.19× | ◆ 0.04× | — | 0.43× | 0.23× -19% | |
| Interest Coverage | 6.89× | ◆ 7.10× | — | 4.54× | 5.82× +18% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹109 Cr | ₹218 Cr | ₹169 Cr | ₹307 Cr | ₹218 Cr -50% | |
| Net Income | ₹17.8 Cr | ₹24.3 Cr | ₹34.7 Cr | — | ₹29.5 Cr -40% | |
| Total Assets | ₹208 Cr | ₹308 Cr | ₹226 Cr | ₹398 Cr | ₹308 Cr -33% | |
| EPS | ₹13.84 | ₹42.14 | — | — | ₹42.14 -67% | |